dupilumab + Matching Placebo + Oral corticosteroids (OCS)
Phase 2/3Completed 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bullous Pemphigoid
Conditions
Bullous Pemphigoid
Trial Timeline
Oct 28, 2020 → Jan 5, 2025
NCT ID
NCT04206553About dupilumab + Matching Placebo + Oral corticosteroids (OCS)
dupilumab + Matching Placebo + Oral corticosteroids (OCS) is a phase 2/3 stage product being developed by Sanofi for Bullous Pemphigoid. The current trial status is completed. This product is registered under clinical trial identifier NCT04206553. Target conditions include Bullous Pemphigoid.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04206553 | Phase 2/3 | Completed |
Competing Products
8 competing products in Bullous Pemphigoid
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ixekizumab | Eli Lilly | Phase 2 | 52 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |
| QGE031 + Placebo | Novartis | Phase 2 | 52 |
| Azathioprine or Mycophenolate mofetil | Roche | Phase 2 | 52 |
| dupilumab | Sanofi | Pre-clinical | 22 |
| BIV009 | Sanofi | Phase 1 | 32 |
| efgartigimod PH20 SC + Prednisone | Argenx | Phase 3 | 74 |
| efgartigimod PH20 SC + Prednisone | Argenx | Phase 2/3 | 62 |